215 related articles for article (PubMed ID: 2661607)
1. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Ko GN; Korpi ER; Kirch DG
J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
[TBL] [Abstract][Full Text] [Related]
2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
3. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
[TBL] [Abstract][Full Text] [Related]
4. Blood levels of haloperidol and clinical outcome in schizophrenia.
Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
[TBL] [Abstract][Full Text] [Related]
5. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
8. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
10. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
Llorca PM; Wolf MA; Lançon C; Bougerol T
Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
[TBL] [Abstract][Full Text] [Related]
11. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
12. Blood levels of haloperidol in schizophrenic patients.
Shvartsburd A; Dekirmenjian H; Smith RC
J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
[TBL] [Abstract][Full Text] [Related]
14. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
15. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Lee BJ; Lee JG; Kim YH
J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
[TBL] [Abstract][Full Text] [Related]
16. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients--a double-blind clinical multicentre investigation.
Heikkilä L; Laitinen J; Vartiainen H
Acta Psychiatr Scand Suppl; 1981; 294():30-8. PubMed ID: 7041517
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
[TBL] [Abstract][Full Text] [Related]
18. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Chang WH; Lin SK; Jann MW
J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
[TBL] [Abstract][Full Text] [Related]
19. The initial US clinical experience in the management of schizophrenic patients with bromperidol.
Gardner E
Acta Psychiatr Belg; 1978; 78(1):134-46. PubMed ID: 347876
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
